Clinical Trials Logo

Nonalcoholic Steatohepatitis clinical trials

View clinical trials related to Nonalcoholic Steatohepatitis.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05084404 Active, not recruiting - Clinical trials for Nonalcoholic Steatohepatitis

Efficacy and Safety of Guanabenz for Nonalcoholic Fatty Liver Disease

Start date: October 29, 2021
Phase: Phase 2
Study type: Interventional

To investigate the efficacy and safety of 4 mg/day of WY-8678 (guanabenz acetate) and 8 mg/day of WY-8678 (guanabenz acetate) in patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH patients) with hypertension

NCT ID: NCT04971785 Active, not recruiting - Clinical trials for Nonalcoholic Steatohepatitis

Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

WAYFIND
Start date: August 9, 2021
Phase: Phase 2
Study type: Interventional

The goals of this clinical study are to learn more about the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firsocostat (CILO/FIR), and understand whether they cause fibrosis improvement and Nonalcoholic Steatohepatitis (NASH) resolution in participants with cirrhosis due to NASH.

NCT ID: NCT04595474 Active, not recruiting - Type 1 Diabetes Clinical Trials

Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes

Start date: January 14, 2021
Phase:
Study type: Observational

The aim of this study is to assess the prevalence of nonalcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes receiving care at Joslin clinic using noninvasive imaging and serum-based methods with the goal of identifying high-risk patients with advanced fibrosis who should be prioritized for specialty referral

NCT ID: NCT02574325 Active, not recruiting - Clinical trials for Nonalcoholic Steatohepatitis

A Study to Assess ARI-3037MO on Hepatic Fat Metabolism in Patients With Dysglycemia and Evidence of Hepatic Steatosis

Start date: October 2015
Phase: Phase 2
Study type: Interventional

Primary objective To investigate the effect of a 24-week, twice daily dosing regimen of ARI-3037MO compared to placebo on plasma triglyceride (TG) levels, liver enzymes and hepatic fat content in patients with dysglycemia and hepatic steatosis due to nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH). Secondary Objective To investigate the safety and tolerability of a 24-week, twice daily dosing regimen of ARI-3037MO compared to placebo in patients with dysglycemia and evidence of NAFLD or NASH.